We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock
FRTX

Delisted

FRTX was delisted on the 18th of December, 2023.

Back to rankings

30 hedge funds and large institutions have $7.15M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

18% more capital invested

Capital invested by funds: $6.08M → $7.15M (+$1.08M)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

11% more funds holding

Funds holding: 27 → 30 (+3)

Holders
30
Holders Change
+3
Holders Change %
+11.11%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
7
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$789K
2
Renaissance Technologies
Renaissance Technologies
New York
+$404K
3
SSWM
Smith Salley Wealth Management
North Carolina
+$306K
4
UBS Group
UBS Group
Switzerland
+$91.3K
5
TI
Telemetry Investments
New York
+$88.8K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$72K
2
Two Sigma Investments
Two Sigma Investments
New York
-$45.1K
3
HF
HRT Financial
New York
-$29K
4
QCG
Quadrant Capital Group
Ohio
-$20K
5
VFA
Valeo Financial Advisors
Indiana
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.48M +$789K +19,182 +50%
Renaissance Technologies
2
Renaissance Technologies
New York
$1.45M +$404K +9,833 +41%
PCM
3
Palisade Capital Management
New Jersey
$905K – – –
TI
4
Telemetry Investments
New York
$580K +$88.8K +2,159 +19%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$535K +$27.6K +671 +6%
SSWM
6
Smith Salley Wealth Management
North Carolina
$361K +$306K +7,440 +755%
Two Sigma Advisers
7
Two Sigma Advisers
New York
$151K +$54.8K +1,333 +61%
Northern Trust
8
Northern Trust
Illinois
$97K – – –
UBS Group
9
UBS Group
Switzerland
$95K +$91.3K +2,220 New
Citadel Advisors
10
Citadel Advisors
Florida
$76K +$73.4K +1,786 New
Morgan Stanley
11
Morgan Stanley
New York
$70K -$1.93K -47 -3%
State Street
12
State Street
Massachusetts
$58K +$55.6K +1,352 New
Bank of New York Mellon
13
Bank of New York Mellon
New York
$57K – – –
Thrivent Financial for Lutherans
14
Thrivent Financial for Lutherans
Minnesota
$50K – – –
BlackRock
15
BlackRock
New York
$36K -$6.25K -152 -15%
TSS
16
Two Sigma Securities
New York
$30K +$28.7K +697 New
SPIA
17
Steward Partners Investment Advisory
New York
$25K – – –
Fifth Third Bancorp
18
Fifth Third Bancorp
Ohio
$24K – – –
Two Sigma Investments
19
Two Sigma Investments
New York
$23K -$45.1K -1,098 -67%
Millennium Management
20
Millennium Management
New York
$17K +$16.6K +403 New
Victory Capital Management
21
Victory Capital Management
Texas
$10K -$206 -5 -2%
CA
22
Cetera Advisors
Colorado
$10K – – –
SFA
23
Sequoia Financial Advisors
Ohio
$10K – – –
NFG
24
Next Financial Group
Texas
$6K -$2.26K -55 -30%
EWM
25
Elmwood Wealth Management
California
$3K – – –
1
2

FRTX Hedge Fund Activity: Q2 2021 in Review

30 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q2 2021, worth a combined $7.15M — up 18% from $6.08M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new FRTX positions and 4 closed out — a net gain of 3 holders — while 7 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $789K. The largest seller was Virtu Financial, exiting entirely with an estimated $72K sold.

  • 30 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q2 2021, up from 27 in Q1 2021.
  • Funds reported $7.15M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q2 2021, up 18% quarter-over-quarter.
  • 7 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q2 2021 and 4 closed out, a net change of +3 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q2 2021 was Vanguard Group, an estimated $789K added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q2 2021 was Virtu Financial, an estimated $72K sold.

Based on aggregated 13F filings for Q2 2021.